Introduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis and patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea.Areas covered: Accumulating evidence supports the role of JAK1/JAK2 pathways in the pathogenesis of graft-versus-host disease (GVHD), and preclinical studies have demonstrated promising efficacy of ruxolitinib in treatment/prevention of GVHD. Early clinical observations that ruxolitinib was effective in treatment of steroid-refractory (SR) acute and chronic GVHD led to the development of prospective clinical trials; Phase II REACH1 (NCT02953678), Phase III REACH2 (NCT02913261), and REACH3 (NCT03112603). Based on the data from the REACH1 trial, ruxolitinib was approved by the FDA in May 2019 for SR acute GVHD in adult and pediatric patients 12 years and older.Expert opinion: Ruxolitinib and other JAK1/JAK2 inhibitors hold promise in other treatment settings such as GVHD prevention and/or first-line therapy.

中文翻译：

---

Ruxolitinib 用于治疗移植物抗宿主病。

简介：鲁索替尼是一种口服选择性 JAK1/JAK2 抑制剂，最初被 FDA 批准用于治疗中 2 或高危骨髓纤维化以及对羟基脲反应不足或不耐受的真性红细胞增多症患者。有证据支持 JAK1/JAK2 通路在移植物抗宿主病 (GVHD) 发病机制中的作用，临床前研究已证明鲁索替尼在治疗/预防 GVHD 中具有良好的疗效。鲁索替尼治疗类固醇难治性 (SR) 急性和慢性 GVHD 的早期临床观察导致前瞻性临床试验的发展；第二阶段 REACH1 (NCT02953678)、第三阶段 REACH2 (NCT02913261) 和 REACH3 (NCT03112603)。基于 REACH1 试验的数据，